Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced Melanoma

Source: OncLive, October 2020

Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the rationale for the ?phase 3 CheckMate-067 trial in advanced melanoma.

?The ?landmark CheckMate-067 trial ?randomized patients with previously untreated, advanced melanoma 1:1:1 to receive nivolumab (Opdivo) plus ipilimumab (Yervoy) followed by nivolumab, nivolumab plus ipilimumab-matched placebo, or ipilimumab plus nivolumab-matched placebo.

During the time of the study, ipilimumab ?monotherapy was considered the standard of care?, says Shoushtari. ?However, nivolumab and pembrolizumab (Keytruda) ?have since become new standards in the space.

READ THE ORIGINAL FULL ARTICLE